These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 22696079)

  • 21. Effect of Combination Therapy of Endothelin Receptor Antagonist and Phosphodiesterase-5 Inhibitor on Clinical Outcome and Pulmonary Haemodynamics in Patients with Pulmonary Arterial Hypertension: A Meta-Analysis.
    Kirtania L; Maiti R; Srinivasan A; Mishra A
    Clin Drug Investig; 2019 Nov; 39(11):1031-1044. PubMed ID: 31420854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Macitentan and morbidity and mortality in pulmonary arterial hypertension.
    Pulido T; Adzerikho I; Channick RN; Delcroix M; Galiè N; Ghofrani HA; Jansa P; Jing ZC; Le Brun FO; Mehta S; Mittelholzer CM; Perchenet L; Sastry BK; Sitbon O; Souza R; Torbicki A; Zeng X; Rubin LJ; Simonneau G;
    N Engl J Med; 2013 Aug; 369(9):809-18. PubMed ID: 23984728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. STRIDE 1: effects of the selective ET(A) receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials.
    Langleben D; Brock T; Dixon R; Barst R;
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S80-4. PubMed ID: 15838366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis.
    Li Q; Kuang HY; Wu YH; Lu TW; Yi QJ
    Medicine (Baltimore); 2019 May; 98(20):e15632. PubMed ID: 31096477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan.
    Shapiro S; Pollock DM; Gillies H; Henig N; Allard M; Blair C; Anglen C; Kohan DE
    Am J Cardiol; 2012 Nov; 110(9):1373-7. PubMed ID: 22858181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.
    Vizza CD; Jansa P; Teal S; Dombi T; Zhou D
    BMC Cardiovasc Disord; 2017 Sep; 17(1):239. PubMed ID: 28874133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.
    Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost AE; Engel PJ; Kramer MR; Burgess G; Collings L; Cossons N; Sitbon O; Badesch DB;
    Ann Intern Med; 2008 Oct; 149(8):521-30. PubMed ID: 18936500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tadalafil therapy for pulmonary arterial hypertension.
    Galiè N; Brundage BH; Ghofrani HA; Oudiz RJ; Simonneau G; Safdar Z; Shapiro S; White RJ; Chan M; Beardsworth A; Frumkin L; Barst RJ;
    Circulation; 2009 Jun; 119(22):2894-903. PubMed ID: 19470885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endothelin receptor antagonists for pulmonary arterial hypertension.
    Liu C; Chen J; Gao Y; Deng B; Liu K
    Cochrane Database Syst Rev; 2009 Jul; (3):CD004434. PubMed ID: 19588356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical trials using vasodilators in pulmonary arterial hypertension: where do we go from here?
    Macchia A; Mariani J; Comignani PD; Tognoni G
    Rev Recent Clin Trials; 2011 Sep; 6(3):228-34. PubMed ID: 21682677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination therapy in pulmonary arterial hypertension: a meta-analysis.
    Bai Y; Sun L; Hu S; Wei Y
    Cardiology; 2011; 120(3):157-65. PubMed ID: 22212696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reliable and developmentally appropriate study end points are needed to achieve drug development for treatment of pediatric pulmonary arterial hypertension.
    Sun H; Stockbridge N; Ariagno RL; Murphy D; Nelson RM; Rodriguez W
    J Perinatol; 2016 Dec; 36(12):1029-1033. PubMed ID: 27416322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials.
    Savarese G; Paolillo S; Costanzo P; D'Amore C; Cecere M; Losco T; Musella F; Gargiulo P; Marciano C; Perrone-Filardi P
    J Am Coll Cardiol; 2012 Sep; 60(13):1192-201. PubMed ID: 22995024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination therapy in pulmonary arterial hypertension.
    Pugh ME; Hemnes AR; Robbins IM
    Clin Chest Med; 2013 Dec; 34(4):841-55. PubMed ID: 24267308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.
    Jing ZC; Parikh K; Pulido T; Jerjes-Sanchez C; White RJ; Allen R; Torbicki A; Xu KF; Yehle D; Laliberte K; Arneson C; Rubin LJ
    Circulation; 2013 Feb; 127(5):624-33. PubMed ID: 23307827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of oral treatments on clinical outcomes in pulmonary arterial hypertension: A systematic review and meta-analysis.
    Zhang HD; Zhang R; Jiang X; Sun K; Wu DC; Jing ZC
    Am Heart J; 2015 Jul; 170(1):96-103, 103.e1-14. PubMed ID: 26093869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension.
    Aypar E; Alehan D; Karagöz T; Aykan HH; Ertugrul İ
    Cardiol Young; 2018 Apr; 28(4):542-547. PubMed ID: 29233198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic Review of Randomized Controlled Trials of Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension.
    Kuntz M; Leiva-Juarez MM; Luthra S
    Lung; 2016 Oct; 194(5):723-32. PubMed ID: 27506903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early decline in six-minute walk distance from the time of diagnosis predicts clinical worsening in pulmonary arterial hypertension.
    Huang J; Mehta S; Mura M
    Respiration; 2015; 89(5):365-73. PubMed ID: 25791910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pulmonary arterial hypertension.
    Wu SC; Caravita S; Lisi E; Pierini S; Dadone V; Todd SE; Gentile F; Secchi MB
    Intern Emerg Med; 2009 Dec; 4(6):459-70. PubMed ID: 19504164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.